Journal
RADIOCHIMICA ACTA
Volume 107, Issue 9-11, Pages 1065-1085Publisher
WALTER DE GRUYTER GMBH
DOI: 10.1515/ract-2019-0005
Keywords
Alpha-emitters; production; separation radiolabeling; targeted alpha therapy; At-211; Bi-212; Ac-225; Bi-213; Th-227; Ra-223; U-230; Th-226
Ask authors/readers for more resources
The use of a-emitting radionuclides in targeted alpha therapy (TAT) holds great potential for treatment of human diseases, such as cancer, due to the short pathlength and high potency of the a particle, which can localize damage to targeted cells while minimizing effects to healthy surrounding tissues. In this review several potential a-emitting radionuclides having emission properties applicable to TAT are discussed from a radiochemical point of view. Overviews of production, radiochemical separation and chelation aspects relative to developing TAT radiopharmaceuticals are provided for the a-emitting radionuclides (and their generator systems) At-211, Ra-224/Pb-212/Bi-212, Ac-225/Bi-213, Th-227/Ra-223, U-230/Th-226, Tb-149 and Fm-255.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available